Potential Biomarkers of the Earliest Clinical Stages of Parkinson’s Disease

Table 2

Relative expression levels of the genes investigated.

Gene	Expression level in untreated patients; Me (25%–75%)	Expression level in treated patients; Me (25%–75%)	Expression level in neurological control; Me (25%–75%)
ALDH1A1	1.08 (0.71–1.53)	1.60 (0.94–2.08)	0.95 (0.33–1.64)
ATP13A2	1.94 (1.43–3.03)^c	2.14 (1.29–4.86)	0.86 (0.46–1.62)
LRRK2	0.44 (0.31–1.26)	0.56 (0.41–1.42)	0.83 (0.37–1.35)
PARK7	1.68 (0.96–2.51)	1.60 (1.32–2.20)	1.00 (0.64–1.50)
PINK1	0.75 (0.25–1.40)	1.29 (0.28–3.37)	0.26 (0.12–0.56)
PDHB	1.46 (0.65–2.16)	2.10 (0.58–2.36)	1.32 (1.01–1.55)
SNCA	0.24 (0.06–1.16)	0.16 (0.04–0.24)	0.14 (0.02–0.99)
ZNF746	2.33 (0.96–4.60)	2.46 (0.66–5.01)	1.07 (0.33–1.64)

Me: median; 25%–75%: 25–75 percentiles. The data in bold are statistically significant ().